MAP3K7 and amyotrophic lateral sclerosis: Previous studies showed that an age-dependent reduction in TAK1 expression is associated with neurodegenerative diseases, such as frontotemporal dementia/amyotrophic lateral sclerosis, and inhibition of RIPK1 was found to alleviate disease-like symptoms[18].